Shield Therapeutics plc·Healthcare

Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript

Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but...

Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but flagged potential headwinds in the US market and announced the departure of its finance chief. The pharmaceutical company, which focuses on iron deficiency treatments, said group net revenues rose to $18 million in the quarter, up from $7 million a year earlier, with EBIT of about $2.5 million compared to a $4.4 million loss previously.
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Healthcare
Drug Manufacturers - Specialty & Generic
63
2019-12-06
1.88